J. Goldman & Co’s Cardiff Oncology CRDF Stock Holding History

J. Goldman & Co’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-47,250	Closed	-$205K	–	505
2024 Q4	$205K	Buy	+47,250	New	+$148K	0.01%	403

Other funds holding CRDF

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

J. Goldman & Co's CRDF Position: Q1 2025 in Review

J. Goldman & Co sold out of Cardiff Oncology (CRDF) in Q1 2025, closing a stake of 47,250 shares — an estimated $205K sold.

J. Goldman & Co first reported a position in CRDF in Q4 2024 and held it in 1 quarter. The position peaked at $205K in Q4 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2025.

J. Goldman & Co reported no remaining Cardiff Oncology position as of Q1 2025 after selling out during the quarter.
J. Goldman & Co sold 47,250 Cardiff Oncology shares in Q1 2025, an estimated $205K.
J. Goldman & Co first reported a position in Cardiff Oncology in Q4 2024 and held it in 1 quarter.
J. Goldman & Co's Cardiff Oncology position peaked at $205K in Q4 2024.
116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2025.

Based on J. Goldman & Co's 13F filing for Q1 2025, filed 15 May 2025.